What's in the Cards for Medifast (MED) This Earnings Season?
Medifast Inc. MED is likely to post an increase in the top and the bottom line when it reports second-quarter 2020 results on Aug 5. The Zacks Consensus Estimate for second-quarter earnings has moved up by a cent to $1.84 in the past 30 days. The estimate suggests an increase of 5.1% from the year-ago quarter’s reported figure. Moreover, the consensus mark for revenues is pegged at $194.8 million that indicates growth of 4.1% from the figure reported in the year-ago quarter.
Notably, this manufacturer and distributor of healthy living products and programs has a trailing four-quarter earnings surprise of 14.8%, on average
MEDIFAST INC Price and EPS Surprise
Key Factors to Note
Medifast is gaining from strength in OPTAVIA — a leading health and wellness communities. In this regard, increase in the number of active earning OPTAVIA coaches is yielding. Also, robust pricing actions undertaken in mid 2019 have been boosting its gross profit margin. Moreover, the company’s actions like floating new incentive plans and promotional offers to stay afloat amid the coronavirus outbreak bode well.
However, Medifast has been grappling with escalated SG&A expenses due to higher OPTAVIA commission, professional service costs along with rise in salaries, benefits and severance. Also, volatile foreign currency movements are a concern.
What the Zacks Model Unveils
Our proven model predicts an earnings beat for Medifast this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Medifast carries a Zacks Rank #2 and an Earnings ESP of +2.53%.
Other Stocks With Favorable Combination
Here are some other companies that you may want to consider as our model shows that these also have the right combination of elements to post an earnings beat.
Nu Skin NUS currently has an Earnings ESP of +10.74% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Flowers Foods FLO currently has an Earnings ESP of +4.49% and a Zacks Rank of 2.
Estee Lauder EL has an Earnings ESP of +9.54% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Click to get this free report
The Estee Lauder Companies Inc. (EL): Free Stock Analysis Report
Nu Skin Enterprises, Inc. (NUS): Free Stock Analysis Report
Flowers Foods, Inc. (FLO): Free Stock Analysis Report
MEDIFAST INC (MED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.